trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['destiny,lung,4', 'lung', 'nsclc', 'destiny,lung02', 'sclc', 'destiny,lung01']
in destiny-lung02, we have a randomization of pts with #her2 mt nsclc (with prior therapy) to the 6.4 mg/kg dose used in destiny-lung01 or a lower, 5.4 mg/kg dose. rr higher at 5.4 (due to maintained intensity from less tox? or imbalance in baseline characteristics?) #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him